Inactive Instrument

Highlights Dermira, Inc.

Equities

US24983L1044

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

QBREXZA Receives Manufacturing and Marketing Approval in Japan Triggering $2.5 Million Payment to Journey Medical Corporation and $7.5 Million to Dermira Inc	22-02-11	CI
Journey Medical Corp completed the acquisition of Qbrexza from Dermira, Inc.	21-04-29	CI
Journey Medical Corp entered into a definitive agreement to acquire Qbrexza from Dermira, Inc. for $160 million.	21-03-30	CI
Evommune, Inc. Enters into an Exclusive License Agreement with Dermira, Inc	21-01-07	CI
Eli Lilly and Company and Dermira Present New Lebrikizumab Phase 2B Clinical Data Showing Patients with Atopic Dermatitis Had Clinically Meaningful Improvements in Itch, Sleep and Quality of Life	20-06-12	CI
Eli Lilly and Company completed the acquisition of 74.8% stake in Dermira, Inc. from a group of sellers.	20-02-18	CI
Eli Lilly and Company entered into an agreement and plan of merger to acquire Dermira, Inc. from a group of sellers for $1.1 billion.	20-01-09	CI
Dermira, Inc. Receives Fast Track Designation from FDA for Lebrikizumab for the Treatment of Atopic Dermatitis	19-12-10	CI
Dermira, Inc. Announces New Scientific Findings Highlighting the Role of Interleukin-13 (IL-13) in Amplifying Itch and the Role Lebrikizumab Plays in Reducing Itch	19-11-14	CI
Dermira, Inc. Provides Sales Guidance for Full Year 2019	19-11-05	CI
Dermira, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-05	CI
Dermira Presents Data from Phase 2B Study of Lebrikizumab in Patients with Atopic Dermatitis at Fall Clinical Dermatology Conference	19-10-17	CI
Dermira Announces Initiation of Phase 3 Program Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis	19-10-09	CI
Dermira, Inc. Provides Sales Guidance for the Full Year of 2019	19-08-07	CI
Dermira, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-07	CI
Almirall Exercises its Option with Dermira to License Rights to Lebrikizumab in Europe for Atopic Dermatitis; Expects to Initiate Phase 3 Program by End of 2019	19-06-25	CI
Dermira, Inc. Reports Consolidated Earnings Results for the First Quarter Ended March 31, 2019	19-05-07	CI
Dermira, Inc. Announces “Life Unfolds” Direct-to-Consumer Campaign to Highlight QBREXZA™ (Glycopyrronium) Cloth	19-03-25	CI
Dermira, Inc. Announces Positive Topline Results from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis	19-03-18	CI
Dermira To Seek Acquisitions	19-03-18	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Dermira, Inc.

Equities

US24983L1044

Highlights

Filters